Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
ID: 351501Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $600K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351501

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-018.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Advanced Development of Informatics Technologies for Cancer Research and Management through a Cooperative Agreement (U24). This funding opportunity aims to enhance emerging informatics technologies that improve the acquisition, management, analysis, and dissemination of cancer-related data, addressing critical areas such as cancer biology, treatment, early detection, and health disparities. With a total funding pool of $3.6 million available for fiscal year 2025, the program will support up to four awards, each with a budget ceiling of $600,000 per year and a maximum project duration of five years. Interested applicants must submit their proposals by November 15, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-018-Full-Announcement.html
    RFA-CA-24-018.html
    The Department of Health and Human Services, through the National Cancer Institute, has issued a Notice of Funding Opportunity (NOFO) for the Advanced Development of Informatics Technologies aimed at enhancing cancer research and management. This initiative invites applications for Cooperative Agreements (U24) focused on the development and refinement of emerging informatics technologies that have shown potential but are not yet widely used in the cancer research landscape. The funding aims to improve the collection, analysis, and interpretation of data relevant to cancer biology, treatment, early detection, prevention, and disparities in cancer care. Key application details include a budget limit of $600,000 per year and a maximum project duration of five years, with a planned funding pool of $3.6 million for up to four awards in fiscal year 2025. The application process is highly competitive, emphasizing collaboration with cancer researchers and integration of user feedback throughout development. Applicants are encouraged to provide comprehensive plans showcasing the significance and innovation of their proposed technologies. Deadline dates for submissions start from May 11, 2024, with final expiration slated for November 16, 2024. Overall, this NOFO emphasizes the critical role of informatics in transforming cancer research methodologies.
    Similar Opportunities
    Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)." This initiative invites currently funded NCI U01 research projects to submit revision applications that propose to enhance their original research questions by integrating new technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The program aims to foster interdisciplinary collaboration and accelerate the validation of emerging technologies that can significantly improve cancer research methodologies. Approximately $700,000 is available for three awards, with each grant providing up to $150,000 annually over a two-year period. Applications are due by October 4, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-006.html.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects that focus on the development and validation of innovative technologies to enhance the quality and handling of cancer-relevant biospecimens, addressing significant gaps in cancer research methodologies. The initiative is part of the National Cancer Institute's (NCI) broader Innovative Molecular Analysis Technologies (IMAT) Program, which seeks to improve cancer biology research, early detection, clinical diagnosis, and treatment, while also tackling health disparities. Eligible applicants can receive up to $300,000 per year for a maximum of three years, with a submission deadline of October 3, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-004.html.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention" under the cooperative agreement mechanism. This initiative aims to support innovative projects that focus on the discovery and development of novel natural products that are safe, nontoxic, and effective in intercepting or preventing cancer, with a structured approach divided into two phases: the UG3 phase for initial target selection and assay validation, followed by the UH3 phase for large-scale evaluations and pharmacokinetic assessments. The total funding available for this program is $4.5 million over the fiscal years 2024 to 2026, with a deadline for applications set for June 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at encouraging revision applications from currently funded NCI P50 specialized centers. This initiative seeks to expand existing research by integrating new technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program, promoting interdisciplinary collaboration to enhance cancer research effectiveness and validation of these technologies. The funding, estimated at $150,000 per award with a total of three awards available, is intended to support projects that aim to reduce cancer risks, improve screening and diagnostic methods, and advance cancer treatments. Applications are due by 5:00 PM local time on October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding initiative aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance the quality, handling, and preservation of cancer-related biospecimens, addressing issues such as pre-analytical degradation. The initiative is part of the broader Innovative Molecular Analysis Technologies (IMAT) Program and seeks to advance cancer research, early detection, and treatment while addressing health disparities. Eligible applicants include a diverse range of institutions and organizations, with a maximum funding amount of $150,000 per year for up to three years. The application deadline is October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at enhancing currently funded NCI R01 research projects. This initiative encourages applicants to propose revisions that integrate new technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program, thereby promoting independent validation and the adoption of innovative tools in cancer research. With an estimated total program funding of $700,000 for approximately three awards in fiscal year 2026, eligible applicants can request up to $150,000 per year for a project period not exceeding two years beyond the parent grant's end date. Key dates include an application opening on March 4, 2025, and a final submission deadline of October 4, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.